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Abstract
The human CXC-chemokine CXCL4 is a potent inhibitor of tumor-induced angiogenesis. Considering that CXCL4 is
sequestered in platelet a-granules and released following platelet activation in the vicinity of vessel wall injury, we tested
the hypothesis that CXCL4 might function as a ligand for integrins. Integrins are a family of adhesion receptors that play a
crucial role in angiogenesis by regulating early angiogenic processes, such as endothelial cell adhesion and migration. Here,
we show that CXCL4 interacts with avb3 on the surface of avb3-CHO. More importantly, human umbilical vein endothelial
cells adhere to immobilized CXCL4 through avb3 integrin, and also through other integrins, such as avb5 and a5b1. We
further demonstrate that CXCL4-integrin interaction is of functional significance in vitro, since immobilized CXCL4
supported endothelial cell spreading and migration in an integrin-dependent manner. Soluble CXCL4, in turn, inhibits
integrin-dependent endothelial cell adhesion and migration. As a whole, our study identifies integrins as novel receptors for
CXCL4 that may contribute to its antiangiogenic effect.
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Introduction
Angiogenesis is the formation of new capillaries from preexisting
blood vessels. Angiogenesis plays an important role in physiologic
processes such as wound healing and in disease progression such as
cancer, diabetic retinopathy and various inflammatory disorders
[1]. In particular, the expansion of solid tumors and other cancers
critically depends on angiogenesis [2], making anti-angiogenesis
strategies relevant for cancer therapy [3]. CXCL4, a CXC-
chemokine, is synthesized predominantly in megakaryocytes,
sequestered in a-granules of platelets, and released upon activation
of platelets [4]. CXCL4 and the peptide derived from its carboxyl-
terminal domain (CXCL4/CTF) display a strong antiangiogenic
activity in vitro [5–7] and in vivo [5,7–8]. They suppress growth of
various tumors [9–11] and metastasis [12] in vivo. This effect is
related to their antiangiogenic action and not to tumor cell
proliferation [8–12]. Although CXCL4 is one of the first agents
discovered to have an antiangiogenic action in ex-vivo systems [5],
the specific receptor mechanisms that transduce the antiangio-
genic signal of CXCL4 are still poorly understood.
Angiogenesis depends on vascular endothelial cell proliferation,
migration and invasion. A family of adhesion receptors known as
integrin receptors tightly regulates these early angiogenic processes.
Indeed, integrins are the major adhesion receptors used by
endothelial cells undergoing angiogenesis to interact with their
extracellular matrix (ECM). This interaction causes spreading of
endothelial cells with cytoskeleton re-organization events necessary
for cells to invade ECM, to proliferate, to migrate and to ultimately
form new tubular vessels [13]. The integrin-dependency of tumor
angiogenesis in vivo is evidenced by the fact that antagonists of the
avb3 integrin, which are highly expressed in angiogenic endothe-
lium, suppress tumor growth by inhibiting angiogenesis [14,15].
Furthermore, the functionally and structurally homologous avb5
has been implicated in angiogenesis under certain conditions and
selective antagonists of avb5 or dual antagonists of avb3 and avb5
integrins inhibit VEGF-stimulated angiogenesis in vivo in animal
models [16]. Finally, the a5b1 integrin was shown to play a crucial
role in angiogenesis and selective antagonists of a5b1 integrin block
tumor angiogenesis, thereby causing regression of human tumors in
animal models [17]. Several integrin inhibitors are currently tested
as therapeutics for cancer [3].
Taking into account that CXCL4 is released from the a-
granules of activated platelets in the vicinity of vessel wall injury
[18] and that CXCL4 targets the endothelial cells in vivo that
undergo active angiogenesis [19,20], we examined the possibility
that CXCL4 might function as a ligand for integrins. We show
here that CXCL4 binds to avb3 and to some extent to avb5 and
a5b1 integrins on the surface of endothelial cells. The CXCL4-
integrin interaction is of functional significance, since CXCL4
modulated endothelial cell functions, such as spreading and
migration through integrins. Taken together with the established
importance of integrin in tumor angiogenesis, this study provides a
new mechanistic context for the function of CXCL4 as an
angiogenesis inhibitor.
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1/Immobilized CXCL4 or CXCL4/CTF induces human
endothelial cell spreading, and focal adhesion kinase
(FAK) phosphorylation
Integrin-mediated cell attachment on cognate integrin ligands,
such as ECM proteins, results in cell spreading, focal adhesion
formation, and tyrosine phosphorylation of intracellular proteins
[21]. When integrin inhibitors such as antibodies are immobilized
on a substrate, they act as agonist and similarly activate intracellular
events [22,23]. To examine whether immobilized CXCL4 would
function as an integrin agonist, HUVECs were plated on coverslips
that had been coatedwithCXCL4.Asshown inFig.1,immobilized
CXCL4 similar to natural integrin ligands fibrinogen or fibronectin,
promoted endothelial cells spreading, focal adhesion and stress
fibers formation. Furthermore, to determine whether the C-
terminus of CXCL4 exhibited similar effects, we used a synthetic
peptide encompassing amino-acid sequence 47–70 (CXCL4/CTF).
Previous data showed that the peptide retains full anti-angiogenic
activity of CXCL4 [5–7]. As shown in Fig. 1, CXCL4/CTF
demonstrated similar effects on endothelial cell spreading, focal
adhesion and stress fibers formation as full length CXCL4.
Furthermore, when HUVECs are plated on a –scrambled peptide
containing amino acides derived from CXCL4/CTF (CXCL4/
CTF-S) (that does not exhibit anti-angiogenic activity), or on
polylysine (to which cells adhere in an integrin-independent
manner), they remained round, and failed to spread and to induce
focal adhesion formation (Fig. 1).
Focal adhesion kinase (FAK) is a 125 kDa cytoplasmic tyrosine
kinase colocalised with integrins at focal adhesion contacts and
rapidly becomes phosphorylated and activated upon integrin
mediated cell adhesion. As shown above, immobilized CXCL4 or
CXCL4/CTF promotes cell spreading with focal adhesion
formation (Fig. 1A). We tested whether these events are sufficient
to activate (tyrosine phosphorylation) FAK. As shown in (Fig. 1B),
attachment of HUVECs to immobilized CXCL4 or CXCL4/
CTF, similar to fibronectin, induced tyrosine phosphorylation of
FAK. As expected, attached cell to polylysine, similar to cells in
suspension, failed to tyrosine phosphorylate FAK. Taken together,
these results suggest that immobilized CXCL4 or CXCL4/CTF
serves as an adhesive ligand to endothelial cells and activates
postligand binding events downstream of integrins.
2/CXCL4 or CXCL4/CTF mediates avb3-CHO cell adhesion
through avb3 integrins
avb3 is expressed on activated endothelial cells. In addition,
inhibition of avb3 by selective antagonists blocks angiogenesis in
response to growth factors in several tumor models [24], indicating
that this integrin plays an essential role in tumor growth dependent
on angiogenesis. Thus, for all these reasons, we first sought to test
the role of avb3 integrin as a putative receptor to the
antiangiogenic factor, CXCL4 and its derived peptide. For this
purpose, we used a CHO cells transfected with avb3( avb3-CHO,
clone A06) and mock-transfected CHO cells. First, we verified
avb3 expression by flow cytometry using a monoclonal antibody
specific for the human avb3 (LM609). In accordance with our
previous data [25], avb3 integrin is highly expressed in avb3-
CHO cells whereas control mock-transfected CHO cells are
negative for avb3 expression (data not shown).
Immobilized CXCL4 or CXCL4/CTF supported avb3-CHO
but not CHO adhesion, in a saturable and concentration-
dependent manner. Quantitative cell attachment assays
demonstrated that immobilized CXCL4 or CXCL4/CTF
supported avb3-CHO cell adhesion, but not mock-transfected
Figure 1. Immobilized CXCL4 or CXCL4/CTF promotes human
umbilical vein endothelial cells (HUVECs) spreading, focal
adhesion and stress fiber formation. (A) Analysis of spreading,
focal adhesion and stress fibers. HUVECs were plated for 4h on
coverslips that had been coated with (25 mg/ml) CXCL4, (25 mg/ml)
CXCL4/CTF, (100 mg/ml) fibrinogen, (25 mg/ml), CXCL4/CTF-S and
(100 mg/ml) poly-D-lysine. After washing, the cells are fixed. The degree
of cell spreading is seen from the phase contrast micrographs (left side)
Then the cells were permeabilized and stained to visualize focal
adhesion (vinculin staining, green), and actin stress fibers (Rhodamin-
Phalloidin staining, red) by confocal microscopy (right side). (B) Analysis
of tyrosine phosphorylation of FAK. Effect of HUVEC cell adhesion to
CXCL4 or CXCL4/CTF on tyrosine phosphorylation of FAK. HUVECs were
maintained in suspension for 60 min (BSA, lane 1) or allowed to attach to
integrins ligand (fibrinogen, lane 4) or CXCL4 (lane 2) or CXCL4/CTF (lane
3). Cells lysates containing equal amounts of protein were immunopre-
cipitated with anti-FAK antibody. One half of immunoprecipitates was
subjected to immunoblotting with anti-phosphotyrosine mAbs, 4G10,
and PY20, and the other half was probed with mAb anti-FAK.
doi:10.1371/journal.pone.0002657.g001
CXCL4 Integrins Angiogenesis
PLoS ONE | www.plosone.org 2 July 2008 | Volume 3 | Issue 7 | e2657CHO cells, in a saturable and concentration-dependent manner
(Fig. 2A). Also, as shown in Fig 2B, adhesion to CXCL4 or CXCL4/
CTF was significantly inhibited by monoclonal antibodies LM609,
A V 1a n dB 3 Aa g a i n s tavb3, ava n db3, respectively. These results
demonstrate that avb3-CHO adhesion on immobilized CXCL4 or
CXCL4/CTF is mediated by avb3 integrin. Consistent with these
results, addition of 10 mM of EDTA, a strong inhibitor of divalent
cation-dependentcellintegrinreceptors,blockstheadhesionofavb3-
CHO cells to CXCL4 or CXCL4/CTF (Fig. 2B). Furthermore, the
incubation of cells with two well established cation activators
integrins, Mn2+ and Mg2+ [26], prior to adhesion of cells to
immobilized CXCL4 or CXCL4/CTF enhances the cell attachment
about 25% (Fig. 2C). These findings indicate that immobilized
CXCL4 or CXCL4/CTF mediates avb3-CHO cell adhesion in a
divalent cation-dependent manner. As with EDTA, addition of
RGD-peptides blocks the adhesion of avb3-CHO to CXCL4 or
CXCL4/CTF, whereas control RGE peptide had no affect on
adhesion (Fig. 2B). These findings suggest that the interaction of
avb3-CHO cells with CXCL4 or -CXCL4/CTF is RGD-
dependent. This is consistent with the idea that avb3i n t e g r i ni sa
CXCL4 receptor in avb3-CHO cells, since avb3 is RGD dependent.
Taken together, these results demonstrate that avb3-CHO cells
attachment on immobilized CXCL4 or CXCL4/CTF is a cation-
dependent process and is avb3i n t e g r i nm e d i a t e d .
CXCL4 and CXCL4/CTF bind to purified integrins. To
reinforcethe resultsdescribedabove,westudiedthedirect interaction
of CXCL4, or CXCL4/CTF, to integrin in a solid-phase ligand
binding assay [27] using a purified human integrin avb3 (protein). As
shown in Fig. 3A, soluble avb3 demonstrates a concentration-
dependent and saturable binding to immobilized CXCL4 or its
peptide CXCL4/CTF. The specificity of the interaction was
confirmed by inhibition of CXCL4 or CXCL4/CTF binding to
avb3i n t e g r i nw i t ht h ei n h i b i t o r yav( A V 1 )a n db3 (B3A) antibodies,
as well with RGD peptides (Fig. 3B). Thus, these results demonstrate
a specific and direct interaction between the angiogenic inhibitor
CXCL4 or its peptide CXCL4/CTF with the avb3 integrin.
Immobilized CXCL4 or CXCL4/CTF promotes avb3-
CHO cell spreading. Confocal analysis showed that
immobilized CXCL4 or CXCL4/CTF promoted avb3-CHO
cell spreading, focal adhesion and stress fibers formation (Fig. 4).
These events were blocked in presence of EDTA or RGD peptides
or with antibodies against avb3. In contrast, mock-transfected
CHO cells did not appreciably spread and generate stress fibers of
actin on CXCL4 or CXCL4/CTF. In addition, when avb3-CHO
cells are plated on a scrambled peptide derived (CXCL4CTF-S),
or on polylysine, they remained round, and failed to spread and to
induce focal adhesion formation (Fig. 4). These results indicate
that immobilized CXCL4 or CXCL4/CTF induces avb3-CHO
cell spreading through avb3 integrins. Collectively, these results
show that CXCL4 or CXCL4/CTF interacts with avb3 integrins
and activates postligand binding event downstream to integrins,
such as cell spreading.
3/Human endothelial cells (HUVECS) adhere on
immobilized CXCL4-, or CXCL4/CTF- through avb3, and
additional integrins, avb5 and a5b1
To investigate the interaction of CXCL4 or CXCL4/CTF with
endogenous integrins, we tested the interaction of CXCL4 or
CXCL4/CTF with integrins expressed on the surface of cultured
HUVECs. We first screened the expression of endogenous integrins
using a flow cytometry analysis. Accordingly with previous data
[28], we found that avb3, avb5a n da5b1 were constitutively
expressed on HUVECs cells using anti-human integrin antibodies
specific for human integrin antibodies specific for avb3 (LM609),
avb5 (P1F6), and a5b1 (HA5) (Fig. 5A). We next studied whether
avb3, avb5a n da5b1 integrins expressed on HUVECs could bind
to CXCL4 or CXCL4/CTF. As shown in Fig. 5B, immobilized
CXCL4 or CXCL4/CTF supported HUVECs cell adhesion in a
saturable and concentration-dependent manner. Adhesion to
CXCL4 or CXCL4/CTF was blocked in presence of RGD
peptides or with antibodies against avb3, thus confirming as above,
that human endothelial cells adhere to immobilized CXCL4 or
CXCL4/CTF through avb3 integrins in an RGD dependent
manner (Fig. 5C). Interestingly, blocking antibodies against avb5
(P1F6) and a5b1 (JBS5), as with avb3, significantly reduced the
adhesion of HUVECs cells on immobilized CXCL4 or CXCL4/
CTF (Fig. 5C). In contrast, blocking antibody against a2b1-integrin
did not affect cell adhesion on immobilized CXCL4 or CXCL4/
CTF (data not shown). Thus, these results demonstrate that
endothelial cells adhere to immobilized CXCL4 or CXCL4/CTF
through avb3, and other integrins, avb5 and a5b1, which play a
crucial role in angiogenesis.
4/Integrin agonists, Mn2+ and PMA, enhance cell
spreading, with focal adhesion and stress fibers
formation, on immobilized CXCL4 or CXCL4/CTF
To further examine the postligand events downstream to
integrins induced by immobilized CXCL4 or CXCL4/CTF, we
examined in more detail cell spreading. As shown above, confocal
analysis shows that immobilized CXCL4 or CXCL4/CTF
promoted cell spreading, focal adhesion and stress fibers formation
(Fig.1,4).When the number ofcellsspreadon differentimmobilized
substrates was quantified, we found that immobilized CXCL4 or
CXCL4/CTF promoted cell spreading by about 50 to 60% in the
absence of integrin agonists. When we analyzed the spreaded cells
by confocal microscopic we found that around 40% of these cells
spread on CXCL4 or CXCL4/CTF (versus 60% with fibronectin,
data not shown) presented focal adhesions with stress fiber
formation (Fig. 6). These events were significantly increased (from
40% to 60%) when we added two-well known integrin activators,
extracellular (Mn2+) and intracellular (Phorbol 12-Mryristate 13
Acetate (PMA) agonists (Fig. 6). These agonists activate avb3
integrin (convert avb3 to a high-affinity conformation) and
stimulate avb3 functions [29], such spreading cells, as well as that
of other integrins [30,31]. Incubation of cells with 250 mM of Mn2+
or 100 nM of PMA produced an increase in both the number of
attached cells and in cell spreading of about 25% and 30%
respectively (Fig. 6). This enhancement was completely blocked by
adding EDTA or RGD (data not shown). This finding suggests that
the interaction of CXCL4 or CXCL4/CTF to integrins, similar to
natural integrin ligands, is subject to integrin function regulation
such as affinity modulation (see Discussion).
5/The ability of CXCL4 to bind to integrin is related to its
anti-angiogenic action
The scrambled control peptide CXCL4/CTF-S fails to inhibit
endothelial cell proliferation [32]. We thus tested whether this
inactive peptide could bind to integrins. We found that, in contrast
with CXCL4/CTF and similar to polylysine, avb3-CHO or
HUVECs plated on immobilized CXCL4/CTF-S peptide did not
adhere significantly. Cells remained round and failed to assemble
focal adhesion and to induce stress fibers (Fig. 1,4). The addition of
the two integrin activators, Mn2+ and PMA, had no effect on the
number of attached cells or on cell spreading on PF-4/CTF-S as
shown by confocal analysis (Fig. 6C). These results suggest that the
ability of CXCL4 and CXCL4/CTF to bind integrins is
correlated with their anti-angiogenic activity.
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PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2657Figure 2. CXCL4 or CXCL4/CTF mediates avb3-CHO cell adhesion through avb3 integrins. In A. Dose dependence of avb3-CHO cell
adhesion to CXCL4 or CXCL4/CTF. avb3-CHO and mock-transfected CHO were plated onto microtiter wells coated with the indicated concentrations
of CXCL4 or CXCL4/CTF and cell attachment was analyzed as described in Material and Methods.I nB , avb3-CHO adhesion to CXCL4 or CXCL4/CTF is
avb3 integrin-dependent. Cells were incubated with the indicated antibodies or RGD-, RGE peptides before plating to wells coated with CXCL4 or
CXCL4/CTF. Anti-integrin antibodies used were: anti-avb3 (LM609), anti-av( AV1), anti-b3 (B3A). Cell attachment was analyzed as above. Error bars
represent the mean6SD, *, P#0.001; **, P#0,00001 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n=4 independent
experiments. In C, adhesion of avb3-CHO to immobilized CXCL4 or CXCL4/CTF is cation-dependent manner. The serum free medium used for the
adhesion assay contained 0.25 mM of Mn2+, or 2 mM of Mg2+. Cell attachment was analyzed as above. Error bars represent the mean6SD,
*, P#0.005 compared to CXCL4 or CXCL4/CTF alone; n=4 independent experiments.
doi:10.1371/journal.pone.0002657.g002
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immobilized fibronectin and vitronectin
To investigate whether CXCL4 or CXCL4/CTF could inhibits
cell adhesion to integrin ligands, we tested the effect of soluble
CXCL4 or CXCL4/CTF on avb3-CHO and HUVECs cells
adhesion to specific avb3 and a5b1 ligands, vitronectin and
fibronectin respectively. We found that the pre-incubation of cells
with soluble CXCL4 or CXCL4/CTF induces cell rounding, and
significantly inhibits cell adhesion to immobilized fibronectin and
vitronectin, in a concentration-dependent manner (Fig. S1).
CXCL4 or CXCL4/CTF did not affect cell adhesion to collagen
I (data not shown). These results suggest that soluble CXCL4 and
CXCL4/CTF act as antagonists of avb3 and a5b1 integrins to
their ligands.
7/immobilized CXCL4 or CXCL4/CTF promotes and
soluble CXCL4 or CXCL4/CTF inhibits endothelial cell
migration in an integrin-dependent and -specific
manners
Cell migration is an essential step in the angiogenesis process
[13]. Previous studies showed that CXCL4 or CXCL4/CTF block
endothelial cell migration in response to FGF-2 or VEGF in
stimulation in vitro [7,33], a process thought to mediate the anti-
angiogenic effect of CXCL4 in vivo. On the other hand, avb3 [34],
and a5b1 [17] integrins have a crucial role in cell migration during
angiogenesis. Taking into account our findings, we determined
whether CXCL4 and its antiangiogenic derived peptide modulates
endothelial cell migration through avb3 and/or a5b1 integrins.
Our finding showed that soluble CXCL4 or CXCL4/CTF
inhibited HUVECs cells migration through fibronectin a reported
avb3 and a5b1 ligand [13], toward VEGF, in a dose depending
manner (Fig. 7A). This migration is similarly inhibited by adding
RGD peptides or by the blocking integrin antibodies, anti-avb3
LM609 or anti-a5b1 JBS5 (Fig. 7A). These results are consistent
with previous data [7,33], and suggest that CXCL4 or CXCL4/
CTF inhibits endothelial cell migration in an integrin dependent
manner.
To study the functional significance of the specific CXCL4-
integrin interaction, we examined the capacity of CXCL4 to
modulate cells functions under conditions in which these functions
are strictly dependent on integrins, and not any other agents. For
this purpose, we use a haptotactic Boyden chamber assay to assess
cell migration in the absence of growth factors, or other soluble
chemoattractants (such as VEGF). Using this assay, previous data
showed that immobilized integrin inhibitors act as functional
agonists and similarly promote integrin functions as cell migration
[22]. On the other hand, cell migration is efficiently inhibited by
the same integrin inhibitors when given in solution to the cells
[22]. We demonstrated that CXCL4 or CXCL4/CTF is similarly
capable of modulating endothelial cell migration. Thus, HUVEC
cells under serum free-medium migrated in a haptotactic Boyden
chamber assay through a CXCL4- or CXCL4/CTF-coated
membrane and this migration was significantly inhibited by
RGD peptides or by the blocking integrin antibodies, anti-avb3
LM609 or anti-a5b1 JBS5 (Fig. 7B). In control experiments,
blocking antibody against a2b1-integrin did not affect cell
migration through CXCL4- or CXCL4/CTF-coated membrane
(Fig. 7B). Soluble CXCL4 or CXCL4/CTF, in turn, interferes
with integrin-dependent cell migration. As shown in (Fig. 7C),
soluble CXCL4 or CXCL4/CTF, but not the inactive peptide
CXCL4/CTF-S, inhibited cell migration on immobilized fibro-
nectin, in a concentration-dependent manner. In control exper-
iments, RGD peptides or blocking antibodies against avo r
a5b12integrin inhibited endothelial cell motility on fibronectin
(Fig. 7C). Soluble CXCL4 and CXCL4/CTF, or antibodies
against av and a5b1 integrins, did not affect cell migration on
collagen I, on which the cells migrated in a manner dependent on
non-RGD binding b1 integrins (data not shown). Thus, immobi-
lized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or
Figure 3. CXCL4 or CXCL4/CTF binds to purified avb3 integrins
in a concentration-dependent and specific manners in solid-
phase ligand binding assay. A. avb3 integrin was added to wells
coated with CXCL4 or CXCL4/CTF as indicated, and incubated overnight
at 4uC. Anti-av, peroxidase-conjugated anti-rabbit IgG antibodies, and
TMB substrate were used to detect bound integrin. B. Soluble RGD-,
RGE peptides or inhibitory anti-integrin antibodies were added to block
the interaction between CXCL4 or CXCL4/CTF and avb3 integrin. Bound
integrin was detected as above. Anti-integrin antibodies used were:
anti-av (AV1) and anti-b3 (B3A). Error bars represent the mean6SD,
*, P#0.005; **, P#0,0005 compared to CXCL4 or CXCL4/CTF in the
presence of IgM control antibody; n=3 independent experiments.
doi:10.1371/journal.pone.0002657.g003
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PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2657Figure 4. Immobilized CXCL4 or CXCL4/CTF promotes avb3-CHO cell spreading, focal adhesion and stress fiber formation. A. avb3-
CHO and mock-transfected CHO cells were plated for 4 h on coverslips that had been coated with (25 mg/ml) CXCL4, (25 mg/ml) CXCL4/CTF, (25 mg/
ml) CXCL4/CTF-S, (100 mg/ml) fibrinogen and (100 mg/ml) poly-D-lysine. After washing, the cells are fixed. The degree of cell spreading is seen from
the phase contrast micrographs (left side). Then the cells were permeabilized and stained to visualize focal adhesion (vinculin staining, green), and
actin stress fibers (Rhodamin-Phalloidin staining, red) by confocal microscopy (right side). B. Effects of function-blocking anti-integrin antibodies and
EDTA and RGD-, RGE-peptides on cell spreading to CXCL4 or CXCL4/CTF. avb3-CHO cells were incubated with 10 mM EDTA or 25 mg/ml of RGD- or
RGE-peptides or 10 mg/ml anti-avb3 (LM609), before plating to coverslips coated with (25 mg/ml) CXCL4 or (25 mg/ml) CXCL4/CTF for 3 h at 37uC.
Wells were washed with PBS, and cells were photographed.
doi:10.1371/journal.pone.0002657.g004
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2657Figure 5. CXCL4-, or CXCL4/CTF-integrin mediates HUVECs adhesion through endogen avb3, avb5 and a5b1 integrins. A. Expression
profile of integrins in HUVECs cells analyzed by flow cytometry. HUVECs were incubated with primary antibodies specific for avb3 (LM609), or avb5
(P1F6), or a5b1 (HA5) and antibody binding was detected with FITC-labeled secondary antibody as described under Materials and Methods. Cells
stained with secondary antibody (2u Ab) only were used as a negative control. B. Dose dependence of HUVECs cell adhesion to CXCL4 or CXCL4/CTF.
HUVECs were plated onto microtiter wells coated with the indicated concentrations of CXCL4 or CXCL4/CTF and cell attachment was analyzed as
described in Material and Methods C. Cell adhesion to CXCL4 and CXCL4/CTF is avb3, avb5 and a5b1 integrins dependent. Cells were incubated with
the indicated antibodies or RGD-, RGE peptides before plating to wells coated with CXCL4 or CXCL4/CTF. Anti-integrin antibodies used were: anti-
avb3 (LM609), anti-av( AV1), anti-b3 (B3A), anti-avb5 (P1F6), anti-a5b1 (JBS5), anti-a5 (P1D6) and anti-b1 (CD29). Cell attachment was analyzed as
above. Error bars represent the mean6SD, *, P#0.001; **, P#0,0001; #,P #0,00001 compared to CXCL4 or CXCL4/CTF in the presence of IgM control
antibody; n=4 independent experiments.
doi:10.1371/journal.pone.0002657.g005
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PLoS ONE | www.plosone.org 8 July 2008 | Volume 3 | Issue 7 | e2657CXCL4/CTF inhibits endothelial cell migration in an integrin-
dependent and -specific manners.
Discussion
We sought to assess whether CXCL4, a CXC chemokine that
exhibit potent anti-angiogenic activities, and its C-terminus
derived peptide CXCL4/CTF, would function as ligands for the
integrin receptors on the surface of endothelial cells. We report
here (1) that CXCL4 or CXCL4/CTF binds to avb3 and to some
extent to avb5 and a5b1 integrins. (2) CXCL4 or CXCL4/CTF
binding to integrins on the surface of avb3-CHO and HUVECs is
blocked by RGD peptide but not by RGE peptide. (3) The
inactive peptide derived from CXCL4/CTF (CXCL4/CTF-S),
fails to interact with integrins on the surface of avb3-CHO or
HUVECs. (4) Immobilized CXCL4 or CXCL4/CTF promotes
avb3-CHO and HUVEC cells spreading, focal adhesion and stress
fibers formation and FAK phosphorylation (5) Functional studies
show that immobilized CXCL4- or CXCL4/CTF support
endothelial cells migration in an integrin-dependent manner and
soluble CXCL4 or CXCL4/CTF, in turn, inhibits integrin-
dependent endothelial cell migration.
Thus, the present study is the first to show that CXCL4
interacts with integrins. This interaction may constitute a novel
mechanism for the inhibitory effects of CXCL4 on angiogenic
blood vessels.
Several lines of cell biological and biochemical evidence
demonstrated the interaction between CXCL4 and integrins in
our study. Thus, inhibitory anti-integrin antibodies prevented
avb3-CHO and HUVEC cell attachment whereas CXCL4
interacted directly with purified avb3 integrin in a specific manner
in a solid-phase binding assay. Despite the fact that neither
CXCL4 nor CXCL4/CTF contain an RGD sequence, the
interaction of CXCL4 with integrins is divalent cation-dependent
and is blocked by RGD peptide. Interestingly, a number of
endogenous angiogenesis inhibitors such as endostatin [27],
arresten [35] canstatin [36] and tumstatin [37,38] also bind
directly to integrin, despite the fact that they lack the RGD-
binding site. For example, the interaction of endostatin with a5b1
integrin is inhibited by RGD peptide, however tumstatin binds to
avb3 in an RGD-independent manner. The fact that the
interaction of CXCL4 with integrins is blocked by the RGD
peptide indicates that CXCL4 interacts with the same or an
overlapping RGD-binding site in integrin. Alternatively, it is
possible that other amino acid sequences within CXCL4 also
interact with the RGD binding site. Interestingly, CXCL4 and
CXCL4/CTF both contain the NGR sequence that is known to
interact with integrins, such as avb3, avb5 and a5b1 [39,40]. The
NGR motif homes to the tumor vasculature, but not in normal
endothelium, through its interaction with integrins. As a
consequence, when coupled to anticancer drugs, the NGR peptide
was shown to enhance their in vivo anti-tumor action and to reduce
their toxicity [41]. Additional studies are required to determine the
sequence motif of CXCL4 that integrins recognize.
Our results show that immobilized CXCL4 or CXCL4/CTF
supported cell spreading, focal adhesion and stress fibers formation
and tyrosine phosphorylation (i.e., activation) of the focal adhesion
kinase (FAK). These events are specific to integrin signaling [21].
This indicates that immobilized CXCL4 or CXCL4/CTF
activates postligand binding events downstream of integrins. The
addition of two well-known integrin activators, Mn2+ -acting as
integrin activator from outside the cells (referred to as outside/in
signaling)- and PMA -activating integrins from inside the cells via
activation of PKC (referred to as inside/out signaling)-, produced
a strong increase in both the number of attached cells and cell
spreading on immobilized CXCL4 or CXCL4/CTF, comparable
to fibrinogen. Thus, PF4 seems to bind to avb3 integrins as a
natural ligand of avb3, such as fibrinogen, which binds with low
affinity to unstimulated avb3 and binds with high affinity to
activated avb3 upon stimulation by agonists, such as Mn2+ or
PMA [29]. Thus, our finding suggests that interaction of CXCL4
or CXCL4/CTF to integrins is subject to integrin function
regulation (i.e. affinity modulation). These results may be relevant
to the antiangiogenic activity of CXCL4 in some pathophysiolog-
ical circumstances in vivo. Indeed, it was shown that the basal
activation state of avb3 varies with the cell type and that an
increase in the number of active avb3 with high affinity for their
ligands is correlated with the acquisition of cell malignancy [29]
and with the metastasis of some cancer, such as in human breast
cancer [42]. Considering that the binding of CXCL4 to integrins
depends on the integrin state (active or not), our results suggest
that the binding of CXCL4 to endothelial cells should increase
during pathological angiogenesis, where affinity modulation of
integrins occurs.
Our results show that soluble CXCL4 or CXCL4/CTF
inhibited endothelial cell adhesion to immobilized matrix proteins,
as fibronectin or vitronectin. These results suggest that soluble
CXCL4 or CXCL4/CTF act as antagonist for integrins avb3 and
a5b1, to mediate its inhibition effect on -endothelial cells
adhesion- angiogenesis. Theoretically, it is possible that CXCL4
could also act on attached endothelial cells by further promoting
spreading. However, we clearly demonstrated that surface
immobilized but not soluble CXCL4 promoted spreading. This
finding argues against a similar effect on already attached cells. In
addition, it is unlikely that spreading of already attached
endothelial cells is inhibited by CXCL4, because of the strong
binding of integrins to matrix proteins.
Although a5b1 is the most abundant integrin on HUVECS
(Fig. 5A), adhesion experiments on immobilized CXCL4 in the
presence of different blocking antibodies against avb3, a5b1, b1,
a5, av, b3 may suggest a greater interaction of CXCL4 to avb3
integrin (Fig. 5C). However this conclusion must be interpreted
with caution because these differences may also be due to more
efficiency antibody binding to avb3 than to a5b1. Also, a
quantitative analysis comparing affinities is required to ascertain
the potentially better interaction of CXCL4 to avb3. Nevertheless,
assuming that CXCL4 interacts better with avb3 than a5b1, we
may speculate that CXCL4 contains additional sequences for
Figure 6. Integrin agonists, Mn2+ and PMA, enhance cell spreading, with focal adhesion and stress fiber formation, on immobilized
CXCL4 or CXCL4/CTF A, B. a. Phase contrast analysis show an enhance of the number of avb3-CHO and HUVECs spreading on immobilized CXCL4
or CXCL4/CTF, upon stimulation with Mn2+ or PMA, b. Confocal analysis show an increase of the number of cell spreading with focal adhesion
(Vinculin staining, green) and stress fibers (Rhodamin-Phalloidin staining, Red) formation in avb3-CHO and HUVECs spread on immobilized CXCL4 or
CXCL4/CTF treated with integrin stimulators, Mn2+ or PMA, as compared with no agonists. C. 100 adherent cells on different substrat were scored for
focal adhesions and stress fibers by two independent observers. Data are the means6SEM of 4 separate experiments. Error bars represent the
mean6SD, *, P#0.005 compared to CXCL4 or CXCL4/CTF in the absence of integrin agonists.
doi:10.1371/journal.pone.0002657.g006
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PLoS ONE | www.plosone.org 9 July 2008 | Volume 3 | Issue 7 | e2657Figure 7. Immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits integrin-dependent endothelial
cell migration. A. Soluble CXCL4 or CXCL4/CTF inhibits migration on fibronectin toward VEGF (5 ng/ml). HUVECs migration was determined in the
presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S or 25 mg/ml of RGD-, RGE peptides or 10 mg/ml of anti-
integrin antibodies (anti-av; AV1 and anti-a5b1; JBS5) as described in Material and Methods. Relative cell migration is indicated, each value is a
mean6SEM from 3 independent experiments. Error bars represent the mean6SD,
#,P #0.05; *, P#0.005, **, P#0.001 compared to the number of cell
migrated in the absence of CXCL4 or CXCL4/CTF or anti-integrin antibodies or RGD peptides. B. Immobilized CXCL4 or CXCL4/CTF supports HUVECs
migration in avb3 and a5b1 integrins-dependent manner. Cell migration assay was performed on immobilized CXCL4 or CXCL4/CTF in serum free
medium and in the presence or absence of inhibitory anti-integrin antibodies or RGD-, RGE peptides. The results at each point are the mean cell
number of 10 randomly selected high magnification microscopic fields. Error bars represent the mean6SD, *, P#0.005; *, P#0.001 compared to
CXCL4 or CXCL4/CTF in the presence of IgG control antibody; n=3 independent experiments. C. Soluble CXCL4 or CXCL4/CTF inhibits migration on
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are significantly up-regulated on endothelial during angiogenesis.
While a5b1 selectively recognizes primarily a single ECM protein
ligand, fibronectin, avb3 can bind several ligands such as
vitronectin, fibronectin, fibrinogen, and other matrix proteins
(13). The fact that CXCL4 may be a better ligand for avb3 than
a5b1, thus blocking the interaction of avb3 integrin to its various
ligands, may increase its inhibitory effect on angiogenesis.
To study the functional significance of the CXCL4-integrin
interaction on angiogenesis, we examined the capacity of CXCL4
to modulate endothelial cell migration. We found that CXCL4
modulates endothelial cell migration, in an integrin-dependent
and -specific manners. Cell migration is a vital step in the
angiogenesis process and is governed by pro-angiogenic factors,
such as VEGF and FGF, and integrins [13,43]. Angiogenic
stimulus by growth factors induces an increased expression of
integrins in endothelial cells undergoing angiogenesis, thereby
leading cells to spread, to migrate and to ultimately form new
tubular vessels [13]. Previous studies showed that both CXCL4
and CXCL4/CTF block endothelial cell migration in response to
VEGF or FGF growth factors [7,33]. This action is believed to
mediate the anti-angiogenic effect of CXCL4, although its
receptor mechanism was not characterized. Here we report that
soluble CXCL4 or CXCL4/CTF, but not the inactive peptide
CXCL4/CTF-S, inhibits endothelial cell migration in avb3 and
a5b1 in an integrin-dependent and -specific manners. Similarly,
endostatin and thrombospondin-1, two endogenous angiogenesis
inhibitors, inhibited endothelial cell migration through b1
integrins [27,44]. Our results suggest that integrins serve as
functional receptors for CXCL4 to mediate its inhibition effect on
-endothelial cells migration- angiogenesis. On the other hand,
other data indicate that VEGF directly activates integrins and
enhance cell migration mediated by avb3 and a5b1 [34]
Furthermore, FGF-2 stimulated endothelial cell migration medi-
ated by avb3 [45]. Further studies are needed to determine the
potential significance of integrin-growth factor receptor cross-talk
in CXCL4 action.
Previous studies showed that CXCL4 and its derived peptide
CXCL4/CTF inhibit angiogenesis by interfering with the
angiogenic effect of the growth factors FGF and VEGF165, either
by directly binding to these angiogenic factors, thereby blocking
their interaction with their specific receptors [32,46–47], or by
competing with the binding of FGF or VEGF to heparan sulfate
proteoglycans on the cell surface [46,48]. Furthermore, CXCL4
was recently shown to bind to CXC3B, a chemokine receptor
isoform that is present in some vascular beds [49]. However, the
role of CXC3-B receptors in the anti-angiogenic function of
CXCL4 remains to be fully established [50]. Our study suggests a
novel additional mechanism for the antiangiogenic effects of
CXCL4, which involves direct targeting of vessel through
integrins. Since integrins are overexpressed in endothelial cells
undergoing angiogenesis, this may explain why, in vivo, CXCL4
tends to preferentially target angiogenic blood vessels [19,20].
Furthermore, this targeting mechanism could be useful for
selective treatments of cancer by CXCL4. Indeed and as
mentioned above, peptides were shown to home selectively in
tumor vasculature, through their interaction with integrins, and
when coupled to anticancer drugs, they enhanced the in vivo anti-
tumor action and reduced the toxicity of anticancer drugs [41].
Finally, integrin-binding of CXCL4 or CXCL4/CTF is also
consistent with a heparan sulfate proteoglycan-independent
mechanism. Indeed, VEGF121, an endothelial cell mitogen that
lacks heparin affinity, is inhibited by CXCL4 [47]. CXCL4 also
antagonizes EGF-mediated endothelial cell proliferation indepen-
dently from glycosaminoglycans [51].
In summary, a general picture of CXCL4’s antiangiogenic
mechanisms is emerging from the results described above. CXCL4
inhibits neovascularization in vivo by several distinct, although not
necessarily exclusive, mechanisms including direct integrin
binding– reported here –, direct interaction with angiogenic
molecules [32], binding to proteoheparan sulfate–which acts as
low affinity co-receptors for growth factors, such as FGF–[46,48]
or activation of CXCR3-B [49]. These different mechanisms may
operate in parallel and in function of the site and/or the type of
vessel that undergo angiogenesis. Additional studies will be
required to fully understand the significance of integrin binding
and other mechanisms involved in CXCL4’s antiangiogenic
activity in vivo.
Materials and Methods
Reagents and Cell Culture
Fibronectin from human, plasma Fibrinogen from human
plasma, poly-D-lysine and bovine serum albumin (BSA, fraction
V) were purchased from Sigma. RGDS and RGES peptides were
from Bachem, human purified platelet factor 4/CXCL4 (CXCL4)
wasobtained from HyphenBioMed, France.C-terminal peptides of
CXCL4, CXCL4/CTF (NGRKICLDLQAPLYKKIIKKLLES)
or CXCL4/CTF-S (LGLKPLKQELIAYRDNK IKSICLK) were
purchased from ThermoHybaid (Ulm, Germany). Purifiedintegrins
and the purified monoclonal anti-human integrin antibodies
LM609 (anti-avb3), P1F6 (anti-avb5), JBS5 and HA5 (anti-a5b1),
B3A (anti-b3), AV1 (anti-av), CD29 (anti-b1), P1D6 (anti-a5) were
purchased from Chemicon. Mouse Ig1 antibody was purchased
from Chemicon. Peroxidase and FITC (Fluorescein isothiocyanate)
conjugated goat anti-mouse immunoglobulins were purchased from
DAKO. Mouse monoclonal anti-human vinculin antibody was
from Sigma and Rhodamin-Phalloidin from Molecular probes. The
Chinese hamster ovary (CHO) cell line CRL9096, as well as CHO
clones expressing human avb3 integrin (avb3-CHO, A06) were
established as described (25). Cells lines were grown at 37uC, 5%
CO2 in Dublecco’s Modified Eagle Medium (GIBCO) supple-
mented with 10% foetal bovine serum, 2 mM glutamine, penicillin
and streptomycin (100 UI/ml) and 1% non-essential amino acids.
Human umbilical vein endothelial cells (HUVECs, Clonetics) were
cultured in EGM medium (Cambrex) supplemented with 10%
foetal bovine serum, 2 mM glutamine, and penicillin and
streptomycin (100 UI/ml). Experimentation was carried out at cell
passage number 4–10.
Flow Cytometry
Analysis cell-surface integrin expression was performed as
described [29]. Cells were suspended in incubation Walsh buffer
(137 mM NaCl, 2.7 mM KCL, 3.3 mM NaH2PO4, 3.8 mM
HEPES, 1 mM MgCl2, 5.5 mM glucose, and 1 mg/ml BSA,
pH 7.4) and 2610
5 cells incubated for 30 min on ice with a
fibronectin. HUVECs migration was determined in serum free medium and in the presence or absence of the indicated concentrations of CXCL4 or
CXCL4/CTF or CXCL4/CTF-S or inhibitory anti-integrin antibodies or RGD-, RGE peptides. Relative cell migration is indicated, each value is a
mean6SEM from 3 independent experiments. Error bars represent the mean6SD,
#,P #0.005; *, P#0.001 compared to the number of cell migrated
in the absence of CXCL4 or CXCL4/CTF or anti-integrin antibodies or RGD peptides.
doi:10.1371/journal.pone.0002657.g007
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avb5 (P1F6), or a5b1 (HA5). After washing, the cells were
incubated for 20 min on ice with FITC-conjugated goat anti-
mouse IgG, washed again, and analyzed on a FACSCalibur flow
cytometer (Becton Dickinson Biosciences). As a negative control,
samples were incubated with the secondary antibody alone.
Cell Attachment Assay
Cell attachment was assayed as described [52]. Microtiter wells
(Immulon 2, ThermoLabsystems) were coated for 2 h at 37uC
with the indicated concentrations of proteins. The wells were
blocked for 1 h with 1% BSA in PBS. Cells were briefly
trypsinized followed by washes with serum-containing medium
and serum-free medium containing 0,5% BSA. Cells were
suspended in 3,5610
5 cells/ml in serum-free medium containing
0,5% BSA and incubated in the presence or absence of 10 mM
EDTA, 25 mg/ml RGD, RGE peptides or 10 mg/ml of anti-
integrin antibodies for 15 min at room temperature. To inhibit
adhesion on various ECMs proteins with soluble CXCL4 or
CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with
cells 30 min in suspension prior plating onto wells, as indicated in
the figures. 100 ml of cells suspensions were added to the coated
wells, and the plates were incubated at 37uC for 60 min. Non
attached cells were removed by washing with PBS and then fixed
and stained in 30% methanol, 10% acetic acid, containing 0,1%
Coomassie blue. After extensive washing, the cells were lysed in
1% SDS, after which the amount of lysed cells were quantified by
measuring their absorbance at 620 nm. Background absorbance
observed in the wells coated with BSA was deducted from the
values obtained. Each time point represented three independent
experiments performed in triplicate.
Solid-Phase Ligand-Binding Assay
Solid-phase ligand binding assay was performed as described
previously with minor modifications [27]. Immulon 2 microtiter
wells were coated with 25 mg/ml CXCL4 or CXCL4/CTF in
PBS overnight at 4uC. The wells were blocked with 1% BSA in
walsh buffer at room temperature for 1 h. Octylglucoside avb3
integrin was added on coated wells and incubated for 2 h at 37uC.
Unbound integrin molecules were extensively washed with walsh
buffer containing 0,05% Tween 20. The bound integrin molecules
were incubated with 1/1000 dilution of a polyclonal anti-av
cytoplasmic domain antibody (Chemicon) for 1 h at room
temperature. After extensive washes with walsh buffer-0,05%
Tween 20, the bound antibodies were detected by using
Peroxidase-Conjugated goat anti-rabbit IgG (Dako). TMB liquid
substrate (sigma) was added to the wells, the reactions were
stopped with 0,5 M H2SO4, and absorbance was measured at
450 nm. Background absorbance in the wells coated with BSA was
deducted from the values obtained.
Cell Spreading and Confocal Microscopy Analysis
Cells were washed twice with serum-free medium, suspended to
the serum-free medium, and plated on coverslips that had been
coated with (25 mg/ml) CXCL4, (25 mg/ml) CXCL4/CTF,
(25 mg/ml) CXCL4/CTF-S, (100 mg/ml) fibrinogen and
(100 mg/ml) poly-D-lysine and incubated at 37uC for 4 h. After
removing nonadherent cells, the adherent cells were fixed in 4%
parafolmaldehyde, permeabilized with 0,2% Triton X-100 in PBS,
and stained with monoclonal anti-vinculin antibody, FITC-anti-
mouse IgG and rhodamine-phalloidin [53]. Cells were analyzed
by confocal laser scanning microscopy and photomicrographs
were prepared using Adobe Photoshop 8.
Analysis of Tyrosine Phosphorylation of FAK
Tyrosine Phosphorylation of FAK was assayed as described [54].
HUVECs were plated for 60 min on dishes that had been coated
with 5 mg/ml of BSA or (100 mg/ml) fibrinogen or (25 mg/ml)
CXCL4 or (25 mg/ml) CXCL4/CTF or (100 mg/ml) poly-D-lysine.
After 60 min, non-adherent cells from BSA-coated plates were
diluted 1:1 with PBS, sedimented at 100 g for 5 min and washed
once with PBS before lysis in complete RIPA buffer (1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS, 158 mM NaCl, 10 mM
Tris, pH 7.4, 1 mM Na2EGTA, 1 mM sodium vanadate, 0.5 mM
leupeptin, 0.25 mg/ml pefabloc, 5 mg/ml aprotinin). The adherent
cells from plates coated with fibrinogen or CXCL4 or CXCL4/CTF
were rinsed twicewith PBS, lysed on the plates with ice-cold complete
RIPA buffer and scrapped into microcentrifuge tubes. Lysates were
incubated for 30 min on ice and clarified supernatants for
immunoprecipitation. Equal amounts of protein from each lysate
(200 mg of protein) were immunoprecipitated with rabbit antiserum
specific for FAK (Santa Cruz). One half of immunoprecipitates were
subjected to western blotting with anti-phosphotyrosine mAbs, 4G10
(BD Transduction Laboratories) and PY20 (Upstate Biotechnology),
and the other halfwasprobed with mAb anti-FAK (BD Transduction
Laboratories). Immunoreactive bands were detected by enhanced
cheminuluminescence detection.
Endothelial cell Migration
Haptotactic cell motility was measured by using a modified
Boyden chamber (BD, Falcon) as previously described [22]. The
undersurface of the membrane filter was coated with 25 mg/ml of
CXCL4 or 25 mg/ml CXCL4/CTF or various matrix proteins.
After washing the membranes with PBS, nonspecific adhesion sites
were saturated with 1% BSA at 22uC for 1 h. HUVECs (3610
4)
were added to the upper chambers in serum-free medium and
were allowed to migrate to the underside of the chamber for 4 h at
37uC. Cell migration was measured after 4 h of incubation at
37uC. All non migrated cells were removed from the upper face of
the membrane filter with the cotton swab and cells migrated to the
lower face were fixed and stained in 30% methanol, 10% acetic
acid, containing 0,1% Coomassie blue. Subsequently, the number
of stained migrated cells (to the lower face of the membrane filter)
was counted. Migration results are expressed in terms of the
average number of cells/high-magnification microscopic field. To
inhibit migration on CXCL4 or CXCL4/CTF, cells with
pretreated with 10 mg/ml of anti-integrin antibodies for 30 min
in suspension prior to plated in chambers. To inhibit migration on
various matrix proteins with soluble CXCL4 or CXCL4/CTF,
CXCL4 or CXCL4/CTF were incubated with cells 30 min in
suspension prior adding to the upper chambers, as indicated in the
figures. In chemotactic cell motility experiments, VEGF (5 ng/ml)
was added in the lower chambers. To inhibit migration on
fibronectin to VEGF with soluble CXCL4 or CXCL4/CTF,
CXCL4 or CXCL4/CTF were incubated with cells 30 min in
suspension prior adding to the upper chambers. In all experi-
ments, nonspecific migration was determined using BSA as a
ligand and was subtracted from the values of relative cell migration
obtained on different matrix proteins.
Statistical Analysis
Student’s test was used to determine the significance of
differences.
Supporting Information
Figure S1 Soluble CXCL4 or CXCL4/CTF inhibits cell
adhesion to fibronectin and vitronectin. HUVECs and avb3-
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PLoS ONE | www.plosone.org 12 July 2008 | Volume 3 | Issue 7 | e2657CHO adhesion on immobilized (10 mg/ml) fibronectin or (10 mg/
ml) vitronectin was determined in the presence or absence of the
indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/
CTF-S as described in Material and Methods. Error bars
represent the mean+SD, #,P ,0.005; *, P,0.001 compared to
the cell adhesion in the absence of CXCL4 or CXCL4/CTF;
n=2 independent experiments.
Found at: doi:10.1371/journal.pone.0002657.s001 (39.08 MB
DOC)
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